Analyst firms · Oppenheimer · AMGN

Oppenheimer AMGN price target and rating history

Amgen Inc. (AMGN) · Health Care

Oppenheimer rates Amgen Inc. (AMGN) Outperform with a $450 price target, as of its latest action on Aug 5, 2026. It has published 3 rating actions on AMGN since February 2022, including 0 upgrades and 0 downgrades. Across 13 firms with a AMGN price target in the last 12 months, the median target is $362. Oppenheimer's $450 is 24% above that.

Current rating
Outperform
Price target
$450
Median target, all firms
$362
Actions on AMGN
3

Oppenheimer price target on AMGN

$450$368$2852023202420252026
Oppenheimer price target on AMGN, each point a stated target, February 2022 to August 2026.

Every Oppenheimer rating on AMGN

How other firms rate AMGN

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
BMO Capital MarketsMarket Perform$450Sep 8, 2026
Truist SecuritiesHold$362Aug 5, 2026
OppenheimerOutperform$450Aug 5, 2026
Morgan StanleyEqual-Weight$351Aug 5, 2026
RBC Capital MarketsOutperform$400Aug 5, 2026
BofA SecuritiesUnderperform$317Aug 5, 2026
Wells FargoEqual Weight$400Aug 5, 2026
Robert W. BairdUnderperform$230Aug 5, 2026
Canaccord GenuityHold$384Aug 5, 2026
Erste GroupHoldMay 5, 2026
JefferiesHold$350Mar 10, 2026
BarclaysEqual Weight$185Feb 20, 2026
BernsteinMkt Perform$335Jan 20, 2026
UBSBuy$380Jan 7, 2026

Questions about Oppenheimer and AMGN

What is Oppenheimer's price target for AMGN?
Oppenheimer's latest stated price target for Amgen Inc. (AMGN) is $450, from its action on Aug 5, 2026.
What is Oppenheimer's rating on AMGN?
Oppenheimer rates AMGN Outperform, a bullish rating, as of Aug 5, 2026.
When did Oppenheimer last change its view on AMGN?
On Aug 5, 2026, Oppenheimer raises its price target to $450 from $400, keeps Outperform.
How does Oppenheimer's AMGN target compare with other analysts?
Across 13 firms with a AMGN price target in the last 12 months, the median target is $362. Oppenheimer's $450 is 24% above that.

More AMGN rating histories

All Oppenheimer ratingsAMGN news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.